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Abstract
Widespread dietary exposure of the population of Britain to bovine spongiform encephalopathy (BSE) prions in the 1980s 
and 1990s led to the emergence of variant Creutzfeldt-Jakob Disease (vCJD) in humans. Two previous appendectomy sample 
surveys (Appendix-1 and -2) estimated the prevalence of abnormal prion protein (PrP) in the British population exposed to 
BSE to be 237 per million and 493 per million, respectively. The Appendix-3 survey was recommended to measure the preva-
lence of abnormal PrP in population groups thought to have been unexposed to BSE. Immunohistochemistry for abnormal 
PrP was performed on 29,516 samples from appendices removed between 1962 and 1979 from persons born between 1891 
through 1965, and from those born after 1996 that had been operated on from 2000 through 2014. Seven appendices were 
positive for abnormal PrP, of which two were from the pre-BSE-exposure era and five from the post BSE-exposure period. 
None of the seven positive samples were from appendices removed before 1977, or in patients born after 2000 and none 
came from individuals diagnosed with vCJD. There was no statistical difference in the prevalence of abnormal PrP across 
birth and exposure cohorts. Two interpretations are possible. Either there is a low background prevalence of abnormal PrP in 
human lymphoid tissues that may not progress to vCJD. Alternatively, all positive specimens are attributable to BSE expo-
sure, a finding that would necessitate human exposure having begun in the late 1970s and continuing through the late 1990s.
Keywords Bovine spongiform encephalopathy · BSE · Variant CJD · vCJD · Surveillance · Subclinical infection · Prion 
protein · PrP · Prion disease · Transmissible proteinopathies · Appendix · Tonsil · Lymphoreticular tissue
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Introduction
The dietary exposure of the population of Britain to 
bovine spongiform encephalopathy (BSE) prions in the 
late 1980s and early 1990s [45] led to the emergence of 
variant Creutzfeldt-Jakob Disease (vCJD) [48]. This form 
of prion disease is characterised by a strain that is differ-
ent from other forms of human prion disease [20], giving 
rise to a distinct clinical picture, biochemical pattern [9] 
and histopathological appearance [48]. People affected by 
vCJD were significantly younger than those succumbing 
to sporadic forms of prion disease [47]. A highly charac-
teristic feature of vCJD is the accumulation of abnormal 
prion protein (abnormal PrP, or also designated  PrPSc), a 
misfolded form of the normal host prion protein  (PrPC) 
[2] in the lymphoreticular system, such as lymph nodes, 
tonsils, spleen and lymphoid follicles in intestinal organs 
[19, 21, 24], something that is absent in sporadic CJD 
[19, 21], or other transmitted forms such as kuru [6, 10] 
or iatrogenic CJD [18]. The presence of abnormal PrP in 
lymphoreticular tissues precedes involvement of the cen-
tral nervous system (CNS) [5, 22] and it was inferred that 
the prevalence of vCJD carrier status in the population 
could be estimated through testing appendix and tonsil 
specimens removed at elective operations.
Whilst the number of clinical vCJD cases so far identi-
fied is relatively small, at 178 in the United Kingdom, it 
is conceivable that a relatively large number of people are 
infected. A particular public health concern is that infected 
individuals might pass the infection to others through sur-
gical instruments, blood donation, or tissue and organ 
donations. This could lead to a self-sustaining secondary 
epidemic of vCJD in the population [16]. Several expen-
sive and ongoing measures are in place to mitigate these 
risks [1, 37, 42]. A number of studies have been conducted 
to improve the accuracy of vCJD abnormal PrP prevalence 
estimates [7, 11, 15].
The first study of appendix and some tonsil tissue (the 
Appendix-1 Study), from operations conducted between 
1995 and 1999, found three positive samples out of 12,674 
screened for abnormal PrP using the immunohistochemis-
try (IHC) technique [23], Supplementary Table 1, online 
resource. This equates to a prevalence of 237 per million 
overall (95% confidence interval (CI) 49–692 per million) 
or one per 4,000 of the British population in the 1961 to 
1985 birth cohort, the cohort in which most vCJD cases 
have arisen.
The second and larger Appendix-2 IHC screening study 
comprised appendix samples from operations conducted 
between 2000 and 2012. Sixteen abnormal PrP prion-
positive samples were found in 32,441 appendix samples 
from those born between 1941 and 1985 (Supplementary 
Tables 1, 2, online resource), a prevalence of 493 per mil-
lion (95% CI 269–1596 per million), or one in 2000, of the 
British population [17]. During completion of Appendix-2, 
the Transmissible Spongiform Encephalopathies (TSE) 
Risk Assessment Subgroup of the Advisory Committee 
on Dangerous Pathogens (ACDP TSE Risk Subgroup), 
the successor to the SEAC (Spongiform Encephalopathy 
Advisory Committee), advised that a further similar sur-
vey should be conducted on tissues from a ‘control’ popu-
lation, i.e. one thought to have been unexposed to BSE.
A third national survey (the Appendix-3 Study) was 
therefore designed to test the hypothesis that there would 
be an absence of samples positive for abnormal PrP in 
appendices removed from people from outside the popula-
tion considered most at-risk of acquiring vCJD from BSE 
via the food chain, i.e. appendices collected from opera-
tions performed either before 1980 (“historical”), or after 
2000 in those born since 1996 (“new”). These periods and 
birth cohorts, in Britain, are composed of persons whose 
exposure to BSE prions through the food chain is expected 
to have been extremely low or negligible. The study was 
designed to be both feasible and sufficiently large to show 
a prevalence difference from Appendix-2 [17]. If there was 
a real prevalence difference, then the observed prevalence 
in the Appendix-3 survey would have needed to be zero 
or very low essentially no more than one positive from 
15,000 or two positives from 20,000 appendix samples.
Materials and methods
The sample collection, data handling and technical pro-
cedures, including equipment and antibodies, were per-
formed as for the Appendix-2 survey [17]. However, the 
inclusion of historical samples dating from the 1960s 
required wax block re-embedding as described below.
Consent and ethics
The unlinked anonymous methodology used in this study 
required all specimens to be irreversibly anonymised 
before any expert examination began (Fig. 1). The design 
ensured there was no possibility of tracing the identity 
of any individual from whom ‘positive’ tissue originated, 
either directly or indirectly, therefore patient consent was 
not required [25]. The study design received a favourable 
ethical opinion from Trent Research Ethics Committee 
(REC reference number: 08/H0405/69). 
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Sample collection, anonymisation, and data 
handling
The study plan was to collect and archive sufficient (up to 
40,000) appendix samples from participating pathology 
departments in Britain, of which 20,000 were from appen-
dectomies that took place before 1980, while another 20,000 
were from operations between 2000 and 2014 from those 
born in 1996 or later. It was anticipated that about 25% of the 
samples would not be suitable for IHC testing, so a sample 
Fig. 1  Flowchart to illustrate the 
pathway of tissue blocks from 
collection, testing and return. a 
Collection of blocks, database 
entry and allocation to bins of 
50 blocks at PHE. Blocks were 
then sent to the participating 
laboratories, where they were 
sectioned and stained. Blocks 
with positive labelling were 
further sectioned (12 sections, 
and 3 × 10 μm paraffin rolls), 
but returned to PHE for unlink-
ing prior to expert examination. 
b Following unlinking, “FEE 
sections” were examined by the 
histopathologists. c Confirma-
tion of a “negative, non-specific, 
suspect, or positive” sample, as 
defined in the Methods section. 
The result was communicated 
to PHE and suspect or positive 
as well as unstained slides were 
sent to the external experts 
(JI, Edinburgh and then DH, 
Plymouth). Additional immu-
nohistochemical preparations 
were prepared in the laboratory 
in Edinburgh when necessary. 
Consensus meetings were held 
to agree on a final assess-
ment and slides were digitally 
archived with whole slide 
imaging
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size of approximately 30,000 would be examined for the 
presence of abnormal PrP.
The source appendix tissues, archived in histology wax 
blocks (formalin fixed, paraffin embedded (FFPE)) were 
collected from 44 hospitals across Britain. Participating 
hospitals (Supplementary Table 12, online resource) were 
visited by trained technical staff from Public Health England 
(PHE) and the Animal and Plant Health Agency (APHA) to 
retrieve samples for inclusion in the study, except where they 
requested to retrieve the samples themselves. Appendectomy 
specimens that met the inclusion criteria were identified by 
searching day books, requisition forms, spreadsheets and/or 
histopathology department databases. Biopsies were mainly 
coded using Systematized Nomenclature of Pathology 
(SNOP) or on the Systematized Nomenclature of Medicine 
(SNOMED) that classified tissue type and morphology as 
numerical codes, thus allowing identification of the target 
specimens and where they were stored. Single blocks from 
each case were selected and couriered in large batches to the 
PHE co-ordinating laboratory.
After application of a study number to each specimen (i.e. 
study-specific sample number), PHE forwarded the appendi-
ces in collections (“bins”) of 50 blocks to the two collaborat-
ing prion screening laboratories, the Department of Neuro-
degenerative Diseases at the UCL Queen Square Institute 
of Neurology (UCL-IoN) and the Pathology Department at 
the APHA laboratory at Weybridge. These laboratories per-
formed sectioning, IHC staining, initial screening and expert 
microscopic examination. After quality assessment of the 
sectioning and IHC staining (see below), and initial screen-
ing, but before expert assessment of the sections, the source 
appendix samples were returned to PHE. Here, details that 
could identify or trace back to any individual patient were 
unlinked from the study number. Non-identifying details 
needed for analysis gender, 5-year birth cohort, and broad 
geographical area where the original appendectomy hospital 
was sited were retained. After this anonymisation step the 
expert examination of the slides commenced (see below and 
flowchart in Fig. 1).
Preparation of sections and immunohistochemical 
detection of abnormal PrP
Five automated Ventana Discovery XT immunohistochemis-
try (IHC) instruments (Roche, Burgess Hill, UK) and identi-
cal protocols were used by the two screening laboratories. 
A primary set of three sections was cut from each appendix 
block. Blocks that were processed and mounted on wooden 
chucks were first re-embedded onto Tissue-Tek cassettes 
to enable microtomy with current equipment. Abnormal 
PrP was detected using mouse monoclonal anti-PrP anti-
bodies KG9 (PrP epitopes aa140-180; Dilution 1:500, TSE 
Resource centre, Roslin Institute Edinburgh, UK) on one 
section and ICSM35 (aa93-102; Dilution 1:1000 of 100 µg/
ml, D-Gen, UK) [4, 11, 15] on a second section and visual-
ised using a peroxidase-diaminobenzidine (DAB) Detection 
Kit (DAB Map Ventana Medical System) [17]. A first micro-
scopic assessment and screening was performed by a histol-
ogy technician to determine the quality of the immunostain-
ing and morphology of the section and to assess whether 
the originating block was of sufficient quality and interest 
to continue through to the secondary preparation stage. At 
this stage, specimens were classified as either ‘non-reactive’, 
‘unsuitable’ or ‘for expert examination’ (FEE) (Fig. 1).
An ‘unsuitable’ sample was defined as lymphoid tissue 
containing fewer than five secondary lymphoid follicles, or 
other (non-appendix) tissue which may have been collected 
or retrieved in error. An ‘FEE’ sample was one in which 
the technician was unsure about what was seen, or which 
showed any evidence suggestive of staining of follicular 
dendritic cells (FDC).
The abnormal accumulation of PrP, i.e. staining detect-
able above the methodological threshold set by technique 
optimisation in control populations, is considered a surro-
gate for detection of abnormal PrP, and henceforth referred 
to as “(accumulation of) abnormal PrP’’. To investigate 
FEE specimens, secondary preparation included repeating 
the staining and/or applying alternative anti-PrP monoclonal 
antibodies (12F10, Cayman Chemical, UK and 3F4, Signet, 
UK). From every FEE block, 17 additional sections were 
prepared and mounted on glass slides for further immu-
nostaining or archiving. In addition, an equivalent of ca. 
30 μm of tissue (usually in two separate cuts) was distributed 
into three Eppendorf tubes (10 μm equivalent per tube) for 
potential future genotyping and other investigations includ-
ing transmission studies.
Four of the 17 slides were immunostained with ICSM35, 
KG9, 12F10 and 3F4 using the same technical procedure 
as described above. Although ‘anonymised’ throughout the 
primary and secondary preparation stages, these slides were 
NOT examined for the presence of abnormal PrP until after 
the ‘unlinking’ stage was complete (Fig. 1).
Expert examination
Expert examination at IoN (SB) or APHA (MMS/YS) cat-
egorised samples as either positive, suspect, non-specific 
or negative (Fig. 1b) [17]. A ‘positive’ sample had to show 
immunostaining of a characteristic FDC network within a 
germinative centre of a follicle and at least one follicle had 
to contain a small network of immunopositive FDCs. The 
positive FDCs had to be present either in the same follicle 
in consecutive sections, or in a different follicle on a deeper 
section. A ‘suspect’ sample would have weak staining in 
a follicle, but in an atypical pattern, or weak or equivocal 
staining not reproduced in consecutive sections. Specimens 
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classified as ‘non-specific’ had non-specific staining, or dif-
fuse reactivity of the entire follicular area, or poor definition 
of the positively labelled cells, or very weak immunoreac-
tivity in all sections including the repeats. Samples were 
classed ‘negative’ when they showed no immunostaining or 
reactivity at all, or presented only non-specific staining of 
non- FDC structures within follicles (such as macrophages, 
non-specific (background) staining inside the follicles), or 
staining of structures outside the follicles such as nerve 
fibres, macrophages, mucosa epithelium and myofibroblasts, 
and occasionally small parasites. All section sets of interest 
(positive and suspect immunostaining) were then referred 
to other experts (JWI) for staining of spare sections at the 
National CJD Research and Surveillance Unit. Each expert 
prepared written reports on each specimen set that were 
returned to the co-ordinating centre without knowledge of 
the other experts’ conclusions on the same specimen set. 
Finally, all the expert histopathologists met, and together 
reviewed each written report and slide set to arrive at a con-
sensus opinion of the findings (Fig. 1c).
Determination of PRNP codon 129 genotype
The PRNP codon 129 genotype of positive samples, and a 
selection of others, was determined using allele discrimina-
tion with minor groove binding (MGB) probes [17]. For pri-
mary assay, an RT-PCR was used, which was confirmed with 
a PCR based restriction endonuclease analysis (Table 1).
Slide management and archiving
After completion of expert examinations, all the stained, 
and any remaining unstained, slides were stored separately 
at both IoN and APHA. Once all testing was completed, 
all of the sets of slides, both stained and unstained, and the 
additional tissue sections, were sent to IoN and stored for 
any follow up investigations on samples that were deemed 
positive or suspect. Images of all slides assessed as positive 
or suspect were digitally archived with a LEICA SCN400 
scanner (LEICA, Milton Keynes UK) at 40 × magnification 
(0.25 μm/pixel) and are stored on a file server hosted by 
UCL. Slides are managed with Leica Slidepath software.
Results
Abnormal PrP accumulation was detected within the FDCs 
of seven appendices out of 29,516 suitable samples exam-
ined. Two of the seven positive samples were from the 
14,692 appendices removed at operations conducted in 1962 
through 1979, and both these positive samples were from the 
5,865 appendices removed in 1977 through 1979 (Fig. 2, 
Supplementary Tables 3, 5 and 6, online resource). The other 
five positive samples were found in the 14,824 appendices 
from people born in 1996 or later and removed at opera-
tion in 2000 through 2014: all five were in the sub-group of 
10,074 born in 1996 through 2000. Therefore, none of the 
seven positive appendices were in specimens removed in 
1976 or earlier, nor in patients born in 2001 or later (Fig. 2, 
Supplementary Table 4, online resource). In addition, using 
the available clinical data on operations involving the 178 
known vCJD cases within the UK, it was deduced that none 
of the seven positive appendices could have been in tissue 
that originated from these known vCJD cases.
Whilst almost all patients with vCJD were homozy-
gous for methionine at PRNP codon 129, in the previous 
Appendix-1 and Appendix-2 Studies, the valine allele was 
present in some of the positive appendix samples, and at a 
higher rate than expected for the UK population genotype 
frequency. In this Appendix-3 Study, four of the seven posi-
tive samples were codon 129 heterozygotes and two of these 
were from the cohort born in 1996 or later (Table 1). There 
was no discernible relationship between the genotypes of 
positive samples in either the Appendix-3 or -2 Studies  and 
the indicators of immunoreactivity ‘strength’ (proportion of 
follicles positive and number of antibodies showing positiv-
ity) (Table 1a, Figs. 2, 3). Moreover, critical appraisal of the 
histological findings in both studies showed no consistent 
differences between any of the positive samples.
The statistical analysis found no difference between the 
prevalence observed in the Appendix-2 Study of 493 per 
million (95% CI: 282 to 801 per million) and the Appen-
dix-3 Study prevalence in appendices removed between 
1962 through 1979 of 136 per million (95% CI: 16–492 
per million; exact p = 0.08), nor with the Appendix-3 Study 
prevalence in appendices from those born in 1996 through 
2000 of 337 per million (95% CI: 110–787 per million; exact 
p = 0.64). When the two groups (before 1980 and after 1996) 
in the Appendix-3 Study were combined, the central preva-
lence estimate for these groups was around 1 in 4,200 (240 
per million), compared with the 1 in 2,000 (500 per million) 
from the Appendix-2 Study. However, this difference is not 
statistically significant. The results are also very similar to 
the Appendix-1 Study which examined samples from the 
1961 through 1985 cohort and found three positive samples 
in roughly 12,000 tested, a rate of positivity of 1 in 4000 
(250 per million).
Further post-hoc investigation of the year of removal of 
appendices in Appendix-3 showed that the samples that 
were positive came from the ‘latest’ taken of the pre-1980 
appendices (both were from 1977–1979 removals, Fig. 2) 
or from the patients born ‘earliest’ in the cohort born from 
1996 (all five were born 1996–2000, Fig. 2), so in both cases 
closer to the population previously considered at higher 
risk. Whilst this is an interesting observation, it should be 
noted that this clustering of cases closer to the higher risk 
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Number of posive over total
follicles Category
x/n %
App 3 - 2206 16/18 89% HIGH pos MV
App 3 - 65257 6/26 23%
LOW
pos pos MV
App 3 - 2071 4/23 17% pos MV
App 3 - 58055 3/25 12% pos MV
App 3 - 58055 1/10 10% pos pos pos MM
App 3 - 66825 2/35 6% pos pos pos MM
App 3 - 55807 1/28 4% MM
App 2 - 28441 25/28 89%
HIGH
pos pos MV
App 2 - 16937 4/5 80% pos MM
App 2 - 32182 12/15 80% pos pos VV
App 2 - 42181 3/4 75% pos MM
App 2 - 42660 3/5 60%
MEDIUM
pos pos pos MM
App 2 - 15048 4/7 57% MV
App 2 - 25173 5/11 45% pos VV
App 2 - 39047 6/16 38% pos pos pos MM
App 2 - 31327 4/11 36% pos pos VV
App 2 - 13119 10/28 35% pos MM
App 2 - 36521 1/4 25% MV
App 2 - 14784 2/10 20%
LOW
pos pos pos VV
App 2 - 25612 2/11 18% MV
App 2 - 38647 6/50 12% pos pos MM
App 2 - 39121 1/9 11% pos pos pos MM
App 2 - 34039 1/41 2% MM
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Table 1  (continued)
Appendix-3 survey data is colour-coded in red hues with red letters and Appendix-2 in blue hues and black letters, with descending intensity 
corresponding to the staining intensity of the follicles). Left column: Survey (App-2 or App-3) and serial number of the sample. The following 
three columns list the results from the ICSM35 staining with percentage of positive follicles in each sample followed by a “category” of staining 
intensity. The next three columns indicate if these follicles were also positively labelled with the other antibodies, KG9, 12F10 and 3F4. The col-
umn on the right indicates the genotype on codon 129 of the PRNP gene
Fig. 2  Outcome of previous, and the current, studies in relation 
to cases of BSE and vCJD. a Incidence of BSE (green) and vCJD 
(orange) in relation to the cohorts of the three studies. The dotted line 
indicates the introduction of the ban of bone meal supplement to cat-
tle feed in 1996. b Cohorts of the Appendix-1 Study, with indication 
of the age at the BSE peak, and the age at appendectomy. Dark blue, 
birth years; orange, appendectomy years; yellow, study years). Red 
dots indicate positive samples in the cohort. c Appendix-2 Study with 
the same birth cohorts as in Appendix-1, with the same age at BSE 
peak, but higher age at appendectomy. 16 positive samples were iden-
tified across the two cohorts. d Current study with illustration of the 
birth cohorts, and the respective ages at the time of appendectomy. 
Two positive samples were identified in the 1970–1979 appendec-
tomy cohort and five samples in the 2000–2015 appendectomy 
cohort. e Illustration of typical staining patterns representative for 
each positive sample (labelled with study number)
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populations was not statistically significant in this post-hoc 
assessment (p = 0.36 for taken 1970–1974 vs. 1975–1976 vs. 
1977–1979, Supplementary Tables 7 and 8, online resource, 
and p = 0.18 for born 1996–2000 vs 2001–2015, Supplemen-
tary Tables 10 and 11, online resource).
Discussion
The Appendix-3 Study was designed to measure the preva-
lence of abnormal PrP in appendices removed in operations 
performed before 1980 (historical), and after 2000 in those 
born since 1996 (new), i.e. in appendices taken from outside 
the population considered most at-risk of acquiring vCJD 
from BSE-related prions in the food chain. The overall prev-
alence of immunopositive samples found in these groups 
that were assumed to be unexposed to BSE was not lower 
than the prevalence in the most highly BSE-exposed cohort 
surveyed in the Appendix-2 Study. Examination of the avail-
able data on the appendectomy history of each human vCJD 
case to date showed that none of the positive appendices 
from this study (Appendix-3), nor the Appendix-2 Study 
[17], could have come from the 178 known vCJD cases in 
the UK.
The absence of a consistent difference between individual 
positive samples within Appendix-3 or between Appendix-2 
and -3 is noteworthy. It might not have been possible to infer 
from these data alone that differences in immunostaining 
pattern of individual samples relate to source or strain, rather 
than host, or age of sample. Had we seen such differences 
it could have suggested different sources for the abnormal 
PrP detected.
One question is whether the IHC staining found in these 
prevalence studies was necessarily related to vCJD. The 
pattern of the staining observed in the positive specimens, 
however, is highly distinctive and consistent with that found 
Fig. 3  Illustration of all positive samples and indication of the ratio 
of positive follicles in each appendix sample. The colour codes indi-
cate negative, weak, intermediate, or strong immunoreactivity with 
ICSM35 immunostaining. No morphological difference of staining 
patterns between the two birth cohorts
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in vCJD cases (both before and after onset of clinical symp-
toms). The abnormal accumulation of PrP in lymphoid tis-
sue, as detected by immunohistochemistry, has only ever 
been found in humans with vCJD, and not in other human 
prion diseases such as sCJD [19, 20], and the transmitted 
forms of iatrogenic CJD [18] or Kuru [6, 10].
Two interpretations of the prevalence of abnormal PrP in 
different populations in Britain may be given. First, there is 
no significant difference in the prevalence of vCJD-related 
abnormal PrP between any of the appendix survey popula-
tions, i.e. there is a low background prevalence of abnor-
mal PrP in human lymphoid tissues that may not progress 
to vCJD. This background prevalence is unrelated to the 
intensity and extent of dietary exposure to BSE. The alter-
native interpretation is that although there is no statistical 
difference in the prevalence of vCJD-related abnormal PrP 
across birth and exposure cohorts in the populations studied, 
the central estimates vary in a direction consistent with the 
changing intensity over time of the observed BSE epidemic 
in cattle. All positive specimens may therefore be attribut-
able to BSE exposure.
This second interpretation, however, suggests that human 
exposure began in the late 1970s and continued through the 
late 1990s, albeit at a much lower rate than in the mid-1980s. 
Although cases of BSE were not described until 1986, back-
calculation models indicate that cases could have been 
occurring, and infectivity possibly entering the food chain, 
for several years before the disease was identified in cat-
tle [8, 46]. In addition, the origins of BSE have never been 
unequivocally established [40], so it could have been present 
at a very low prevalence for a long time prior to its ampli-
fication through the animal feed chain [46]. Cases of BSE 
continued to occur in animals born after the total feed ban 
put in place in the UK in July 1996, the reinforced feed ban 
in Ireland in October of the same year and the total feed ban 
in the rest of EU in 2001 [40], and such cases could provide 
one possible route of exposure for the vCJD cases identified 
in the post-1996 birth cohort.
Additionally, it has been demonstrated that sheep are 
susceptible to BSE [30, 44], and the disease can transmit 
between sheep under field conditions [31]. It has never been 
isolated from commercial sheep populations, but it has been 
observed in goats [43]. Sheep-passaged  BSE can demon-
strate increased ‘virulence’ on subsequent inter-species 
transmission [38, 44], and can cause disease indistinguish-
able from vCJD in transgenic mouse models [32, 38]. A non-
bovine route of exposure is therefore hypothetically possible.
Neither interpretation, on its own, is entirely satisfactory 
and it is possible to speculate about a combination of both. 
There could be ‘background’ prevalence in all groups plus 
some additional prevalence associated with BSE in the most 
highly exposed population. Detailed appraisal of the histo-
logical findings, however, showed no consistent differences 
between the positive samples that might have indicated 
two or more different sources. A large study of a popula-
tion entirely unexposed to BSE prions would be necessary 
to determine whether a background prevalence exists, and 
such a study would pose additional challenges to those faced 
when implementing the Appendix-3 survey.
Whichever interpretation is preferred, the contrast 
between the prevalence of abnormal PrP and the number of 
clinical vCJD cases seen to date (mid-2020) strongly sug-
gests that possibly none of those in whom abnormal PrP is 
detected through an ante-mortem lymphoid tissue survey 
will develop any symptoms of prion disease.
New research proposals have been sought that utilise 
some of the archived additional slides and cuts of forma-
lin fixed tissues from each positive appendix [Department 
of Health Policy Research Programme—Research call on 
vCJD 2016: https ://clahr cproj ects.co.uk/news/depar tment 
-healt h-polic y-resea rch-progr amme-invit ation -appli catio ns] 
(accessed March 2020). In response, laboratory investiga-
tions are underway to elucidate the nature of the immuno-
positive samples. One approach is using in vitro conversion 
models to amplify the abnormal prion prior to conducting 
Western blotting analysis and transmission studies in mice 
(Green A; personal communication). Another is attempting 
discrimination of vCJD infected from uninfected fixed tis-
sues through DNA methylation array “profiling” (Mead S; 
personal communication).
A variety of risk management measures remain in place to 
limit the risks of person-to-person transmission of prions by 
blood transfusion or by re-use of surgical instruments in the 
general population. Whichever way the Appendix-3 Study is 
interpreted, the prevalence range of prion infection remains 
a concern, and maintenance of the full range of precaution-
ary measures is a judgement that would need to be balanced 
against the costs and benefits of these risk reduction meas-
ures [1, 37, 42]. More specifically, it is reasonable to assume 
that the highest prevalence of asymptomatic infection is in 
the cohort that had greatest exposure to BSE and which con-
tains all known clinical cases of vCJD, the 1961 to 1985 
birth cohort [36]. The findings of the Appendix-3 Study, 
however, challenge the assumption that a specific cut-off 
date defines a low-risk population, i.e. those born after 1996. 
Therefore, the difference between the interpretations of the 
Appendix-3 prevalence has practical implications for risk 
management.
The discovery that not only PrP but also other proteo-
pathic seeds such as amyloid-β can be iatrogenically trans-
mitted between humans has in the last few years received 
significant attention [33]. Whilst experimental transmis-
sion of amyloid-β had been demonstrated for some years 
[12, 13, 34], the observation of human transmission of 
amyloid-β through contaminated human growth hormone 
[28, 33, 41] has prompted additional studies examining 
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the potential transmission through other human-derived 
products such as dura mater transplants [14, 35], intra-
vascular embolization material [3], and through surgical 
instruments [29]. The transmissibility into susceptible ani-
mals of amyloid-β contained in human growth hormone 
preparations has provided further evidence of the historic 
role of this product in the development of cerebral amyloid 
angiopathy (CAA), a potentially lethal vascular disease, 
in affected individuals [26, 39]. These observational and 
experimental studies have put new emphasis on the neces-
sity of adequate surveillance of relevant human diseases, 
sensitive detection of proteopathic seeds other than PrP 
[27] and their effective decontamination, for example on 
surgical instruments and medical devices.
In conclusion, the Appendix-3 Study has not produced 
a clear answer to the question of whether the presence of 
abnormal PrP, as detected by IHC, in the British popula-
tion is limited to those exposed to the BSE epizootic. The 
results raise the possibility of abnormal prion exposure 
both before the presumed BSE epizootic and after 1996 
when exposure to BSE-related prions in the food chain in 
Britain was considered “extremely low”.
Acknowledgements We thank Jessica Broni and Francesca Launch-
bury (UCL Queen Square Institute of Neurology) and Linda Powell, 
Sarah Marsh and the Pathology Unit histology team (APHA) for excel-
lent histological assistance. We also thank Dr Diane Ritchie in the 
National CJD Research & Surveillance Unit for expert assistance in 
the staining and assessment of sections for review. We also thank the 
participating hospitals for providing us with archival histological sam-
ples (List of hospitals in Supplementary Table 12, online resource).
Author contributions Conception and design, or analysis and inter-
pretation of data: NG, YS, ARL, CK, DB, RD, JL, DE, MS, PB, NA, 
DAH, JWI, JB, MP, SM, SB KS; Drafting the article or revising it 
critically for important intellectual content: SB, NG, JWI, DH, MS, 
SM; Final approval of the version to be published: NG, SB; Name of 
the guarantor(s) for the study: NG, SB.
Funding This was an independent scientific survey commissioned 
and funded by the Policy Research Programme of the Department of 
Health, UK. The views expressed in the publication are those of the 
authors and not necessarily those of the UK Department of Health. 
Simon Mead is an NIHR Senior Investigator. Some of this work was 
funded by the Medical Research Council UK (SM) and the National 
Institute of Health Research’s (NIHR) Biomedical Research Centre at 
UCL Hospitals NHS Foundation Trust (SM, SB).
Compliance with ethical standards 
Conflict of interest NG and CK have support from the Department of 
Health and SB, JL, ARL, LB, MS, PB, DE and YS were in receipt of a 
Grant from Public Health England to carry out the submitted work; (2) 
None of the authors has a relationships with any company that might 
have an interest in the submitted work in the previous 3 years; (3) their 
spouses, partners, or children have no financial relationships that may 
be relevant to the submitted work; and (4) none of the authors non-
financial interests that may be relevant to the submitted work.”
Ethical approval See materials and methods for details.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Advisory Committee on the Safety of Blood, Tissues and Organs 
(SaBTO) (2019) Paediatric Components Working Group-Report: 
Importation of plasma and use of apheresis platelets as risk reduc-
tion measures for variant Creutzfeldt-Jakob Disease. City, pp 1–60
 2. Aguzzi A, Weissmann C (1997) Prion research: the next frontiers. 
Nature 389:795–798. https ://doi.org/10.1038/39758 
 3. Banerjee G, Adams ME, Jaunmuktane Z, Lammie GA, Turner 
B, Wani M et al (2019) Early onset cerebral amyloid angiopa-
thy following childhood exposure to cadaveric dura. Ann Neurol 
85:284–290. https ://doi.org/10.1002/ana.25407 
 4. Bell JE, Gentleman SM, Ironside JW, McCardle L, Lantos PL, 
Doey L et al (1997) Prion protein immunocytochemistry–UK five 
centre consensus report. Neuropathol Appl Neurobiol 23:26–35
 5. Bishop MT, Diack AB, Ritchie DL, Ironside JW, Will RG, Man-
son JC (2013) Prion infectivity in the spleen of a PRNP heterozy-
gous individual with subclinical variant Creutzfeldt-Jakob disease. 
Brain 136:1139–1145. https ://doi.org/10.1093/brain /awt03 2
 6. Brandner S, Whitfield J, Boone K, Puwa A, O’Malley C, Line-
han JM et al (2008) Central and peripheral pathology of kuru: 
pathological analysis of a recent case and comparison with other 
forms of human prion disease. Philos Trans R Soc Lond B Biol 
Sci 363:3755–3763. https ://doi.org/10.1098/rstb.2008.0091
 7. Clewley JP, Kelly CM, Andrews N, Vogliqi K, Mallinson G, Kai-
sar M et al (2009) Prevalence of disease related prion protein in 
anonymous tonsil specimens in Britain: cross sectional opportun-
istic survey. BMJ 338:b1442. https ://doi.org/10.1136/bmj.b1442 
 8. Cohen CH, Valleron AJ (1999) When did bovine spongiform 
encephalopathy (BSE) start? Implications on the prediction of a 
new variant of Creutzfeldt-Jakob disease (nvCJD) epidemic. Int J 
Epidemiol 28:526–531. https ://doi.org/10.1093/ije/28.3.526
 9. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF (1996) Molecu-
lar analysis of prion strain variation and the aetiology of ’new 
variant’ CJD. Nature 383:685–690. https ://doi.org/10.1038/38368 
5a0
 10. Collinge J, Whitfield J, McKintosh E, Frosh A, Mead S, Hill AF 
et al (2008) A clinical study of kuru patients with long incuba-
tion periods at the end of the epidemic in Papua New Guinea. 
Philos Trans R Soc Lond B Biol Sci 363:3725–3739. https ://doi.
org/10.1098/rstb.2008.0068
 11. de Marco MF, Linehan J, Gill ON, Clewley JP, Brandner S (2010) 
Large-scale immunohistochemical examination for lymphoreticu-
lar prion protein in tonsil specimens collected in Britain. J Pathol 
222:380–387. https ://doi.org/10.1002/path.2767
 12. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson 
LH, Yan ZX et al (2009) Induction of cerebral beta-amyloidosis: 
975Acta Neuropathologica (2020) 139:965–976 
1 3
intracerebral versus systemic Abeta inoculation. Proc Natl Acad 
Sci USA 106:12926–12931. https ://doi.org/10.1073/pnas.09032 
00106 
 13. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, 
Wolburg H et al (2010) Peripherally applied Abeta-containing 
inoculates induce cerebral beta-amyloidosis. Science 330:980–
982. https ://doi.org/10.1126/scien ce.11945 16
 14. Frontzek K, Lutz MI, Aguzzi A, Kovacs GG, Budka H (2016) 
Amyloid-beta pathology and cerebral amyloid angiopathy are 
frequent in iatrogenic Creutzfeldt-Jakob disease after dural graft-
ing. Swiss Med Wkly 146:w14287. https ://doi.org/10.4414/
smw.2016.14287 
 15. Frosh A, Smith LC, Jackson CJ, Linehan JM, Brandner S, Wads-
worth JD et al (2004) Analysis of 2000 consecutive UK tonsillec-
tomy specimens for disease-related prion protein. Lancet 364:1260–
1262. https ://doi.org/10.1016/S0140 -6736(04)17143 -2
 16. Garske T, Ward HJ, Clarke P, Will RG, Ghani AC (2006) Fac-
tors determining the potential for onward transmission of variant 
Creutzfeldt-Jakob disease via surgical instruments. J R Soc Interface 
3:757–766. https ://doi.org/10.1098/rsif.2006.0142
 17. Gill ON, Spencer Y, Richard-Loendt A, Kelly C, Dabaghian R et al 
(2013) Prevalent abnormal prion protein in human appendixes after 
bovine spongiform encephalopathy epizootic: large scale survey. 
BMJ 347:f5675. https ://doi.org/10.1136/bmj.f5675 
 18. Head MW, Ritchie D, Smith N, McLoughlin V, Nailon W, Samad 
S et al (2004) Peripheral tissue involvement in sporadic, iatrogenic, 
and variant Creutzfeldt-Jakob disease: an immunohistochemical, 
quantitative, and biochemical study. Am J Pathol 164:143–153. https 
://doi.org/10.1016/S0002 -9440(10)63105 -7
 19. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas 
DJ, Frosh A et al (1999) Investigation of variant Creutzfeldt-Jakob 
disease and other human prion diseases with tonsil biopsy samples. 
Lancet 353:183–189. https ://doi.org/10.1016/s0140 -6736(98)12075 
-5
 20. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge 
J et al (1997) The same prion strain causes vCJD and BSE. Nature 
389(448–450):526. https ://doi.org/10.1038/38925 
 21. Hill AF, Zeidler M, Ironside J, Collinge J (1997) Diagnosis of new 
variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 349:99–
100. https ://doi.org/10.1016/S0140 -6736(97)24002 -X
 22. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J (1998) 
Prion immunoreactivity in appendix before clinical onset of vari-
ant Creutzfeldt-Jakob disease. Lancet 352:703–704. https ://doi.
org/10.1016/s0140 -6736(98)24035 -9
 23. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie 
D et al (2004) Prevalence of lymphoreticular prion protein accu-
mulation in UK tissue samples. J Pathol 203:733–739. https ://doi.
org/10.1002/path.1580
 24. Hilton DA, Sutak J, Smith ME, Penney M, Conyers L, Edwards P 
et al (2004) Specificity of lymphoreticular accumulation of prion 
protein for variant Creutzfeldt-Jakob disease. J Clin Pathol 57:300–
302. https ://doi.org/10.1136/jcp.2003.01227 8
 25. Human Tissue Authority (2009) Code of Practice Consent Part 3 
Tissue from the living https ://www.hta.gov.uk/hta-codes -pract ice-
and-stand ards-0. Accessed 20 Feb 2020.
 26. Huynh TV, Holtzman DM (2018) Amyloid-beta ’seeds’ in old vials 
of growth hormone. Nature 564:354–355. https ://doi.org/10.1038/
d4158 6-018-07604 -6
 27. Jaunmuktane Z, Brandner S (2019) Invited review: the role of prion-
like mechanisms in neurodegenerative diseases. Neuropathol Appl 
Neurobiol. https ://doi.org/10.1111/nan.12592 
 28. Jaunmuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny 
J et al (2015) Evidence for human transmission of amyloid-beta 
pathology and cerebral amyloid angiopathy. Nature 525:247–250. 
https ://doi.org/10.1038/natur e1536 9
 29. Jaunmuktane Z, Quaegebeur A, Taipa R, Viana-Baptista M, Bar-
bosa R et al (2018) Evidence of amyloid-beta cerebral amyloid 
angiopathy transmission through neurosurgery. Acta Neuropathol 
135:671–679. https ://doi.org/10.1007/s0040 1-018-1822-2
 30. Jeffrey M, Ryder S, Martin S, Hawkins SA, Terry L, Berthelin-
Baker C et al (2001) Oral inoculation of sheep with the agent of 
bovine spongiform encephalopathy (BSE). 1. Onset and distribution 
of disease-specific PrP accumulation in brain and viscera. J Comp 
Pathol 124:280–289. https ://doi.org/10.1053/jcpa.2001.0465
 31. Jeffrey M, Witz JP, Martin S, Hawkins SA, Bellworthy SJ, Dexter 
GE et al (2015) Dynamics of the natural transmission of bovine 
spongiform encephalopathy within an intensively managed sheep 
flock. Vet Res 46:126. https ://doi.org/10.1186/s1356 7-015-0269-x
 32. Joiner S, Asante EA, Linehan JM, Brock L, Brandner S, Bell-
worthy SJ et al (2018) Experimental sheep BSE prions generate 
the vCJD phenotype when serially passaged in transgenic mice 
expressing human prion protein. J Neurol Sci 386:4–11. https ://doi.
org/10.1016/j.jns.2017.12.038
 33. Jucker M, Walker LC (2015) Neurodegeneration: amyloid-beta 
pathology induced in humans. Nature 525:193–194. https ://doi.
org/10.1038/52519 3a
 34. Jucker M, Walker LC (2013) Self-propagation of pathogenic protein 
aggregates in neurodegenerative diseases. Nature 501:45–51. https 
://doi.org/10.1038/natur e1248 1
 35. Kovacs GG, Lutz MI, Ricken G, Strobel T, Hoftberger R, Preusser 
M et al (2016) Dura mater is a potential source of Abeta seeds. 
Acta Neuropathol 131:911–923. https ://doi.org/10.1007/s0040 
1-016-1565-x
 36. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bel-
lenguez C et al (2013) Meta-analysis of 74,046 individuals identi-
fies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 
45:1452–1458. https ://doi.org/10.1038/ng.2802
 37. National Institute for Health and Care Excellence (2020) Reducing 
the risk of transmission of Creutzfeldt–Jakob disease (CJD) from 
surgical instruments used for interventional procedures on high-risk 
tissues (IPG666). https ://www.nice.org.uk/guida nce/ipg66 6
 38. Padilla D, Beringue V, Espinosa JC, Andreoletti O, Jaumain E, Reine 
F et al (2011) Sheep and goat BSE propagate more efficiently than 
cattle BSE in human PrP transgenic mice. PLoS Pathog 7:e1001319. 
https ://doi.org/10.1371/journ al.ppat.10013 19
 39. Purro SA, Farrow MA, Linehan J, Nazari T, Thomas DX, Chen Z 
et al (2018) Transmission of amyloid-beta protein pathology from 
cadaveric pituitary growth hormone. Nature 564:415–419. https ://
doi.org/10.1038/s4158 6-018-0790-y
 40. Ricci A, Allende A, Bolton D, Chemaly M, Davies R, Fernández 
Escámez PS et al (2017) Bovine spongiform encephalopathy (BSE) 
cases born after the total feed ban. EFSA J 15:e04885. https ://doi.
org/10.2903/j.efsa.2017.4885
 41. Ritchie DL, Adlard P, Peden AH, Lowrie S, Le Grice M et al (2017) 
Amyloid-beta accumulation in the CNS in human growth hormone 
recipients in the UK. Acta Neuropathol 134:221–240. https ://doi.
org/10.1007/s0040 1-017-1703-0
 42. Seed CR, Hewitt PE, Dodd RY, Houston F, Cervenakova L (2018) 
Creutzfeldt-Jakob disease and blood transfusion safety. Vox Sang 
113:220–231. https ://doi.org/10.1111/vox.12631 
 43. Spiropoulos J, Lockey R, Sallis RE, Terry LA, Thorne L, Holder 
TM et al (2011) Isolation of prion with BSE properties from farmed 
goat. Emerg Infect Dis 17:2253–2261. https ://doi.org/10.3201/eid17 
12.11033 3
 44. Torres JM, Espinosa JC, Aguilar-Calvo P, Herva ME, Relano-
Gines A et al (2014) Elements modulating the prion species barrier 
and its passage consequences. PLoS ONE 9:e89722. https ://doi.
org/10.1371/journ al.pone.00897 22
 45. Wells GA, Scott AC, Johnson CT, Gunning RF, Hancock RD, Jeffrey 
M et al (1987) A novel progressive spongiform encephalopathy in 
cattle. Vet Rec 121:419–420. https ://doi.org/10.1136/vr.121.18.419
976 Acta Neuropathologica (2020) 139:965–976
1 3
 46. Wilesmith JW, Ryan JB, Hueston WD, Hoinville LJ (1992) Bovine 
spongiform encephalopathy: epidemiological features 1985 to 1990. 
Vet Rec 130:90–94. https ://doi.org/10.1136/vr.130.5.90
 47. Will RG, Cousens SN, Farrington CP, Smith PG, Knight RS, Iron-
side JW (1999) Deaths from variant Creutzfeldt-Jakob disease. Lan-
cet 353:979. https ://doi.org/10.1016/s0140 -6736(99)01160 -5
 48. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alp-
erovitch A et al (1996) A new variant of Creutzfeldt-Jakob disease 
in the UK. Lancet 347:921–925. https ://doi.org/10.1016/s0140 
-6736(96)91412 -9
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
